Minimal clinically important differences for measures of treatment efficacy in StevensJohnson syndrome and toxic epidermal necrolysis
To the Editor: There is a lack of evidence for benefit of any specific treatment for Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). 1 The purpose of this study was to survey North American dermatologists and burn surgeons to estimate the minimally clinical important difference (MCID) in key outcomes for assessing treatment efficacy in SJS and TEN. MCID provides a measure of the smallest change in a specific treatment outcome that clinicians perceive as important and practice-changing. MCID are needed to effectively evaluate treatment efficacy in a clinically meaningful way for physicians. Establishing the MCID is the first step in designing rigorous randomized controlled trials to evaluate treatments for SJS and TEN. There is a lack of clinical trials for these life-threatening conditions, and this study lays the essential groundwork for future trial design.
A survey was designed to estimate MCID values for a) length of time to achieve full reepithelialization (complete healing), b) length of time before cessation of disease progression, c) length of hospital stay, and 4) rate of mortality. This confidential and anonymous survey (constructed using SurveyMonkey, San Mateo, California) was electronically disseminated to a total of 928 dermatologists and burn surgeons who specialize in SJS and TEN care across North America. Participants were identified through registries from specialty-specific associations including the Canadian Dermatology Association, American Burn Association, and contact lists of North American physicians from previous survey efforts on SJS and TEN. A total of 190 physicians completed the survey (response rate of 20.5%). Weighted means with standard deviations and standard errors of the mean were used. Demographics of survey participants are summarized in Table I . The estimated MCID for full re-epithelialization (complete healing) was 3.2 6 1.8 days (SEM 0.7 days). The estimated MCID for time to cessation of disease progression was 2.1 6 1.5 days (SEM 0.7 days). The estimated MCID for time reduction in length of hospital stay was 2.7 6 1.6 days (SEM 0.7 days). The estimated MCID for reduction in rate of mortality was 2%-10%.
With this survey data, we defined a set of MCID estimates for treatment outcomes specific to SJS and TEN and estimated the MCID values from weighted means with standard deviations to provide a clinically meaningful consensus estimate (Fig 1) . As perceived by physicians, these values would constitute clinically important changes required to change practice in the management of SJS and TEN.
The strengths of the study are the large size of the cohort, high response rate, representativeness, and reproducibility of the survey. However, MCID estimates are not easily verifiable against external objective measures. In addition, the cross-sectional survey design can introduce biases, such as recall bias.
Our study is the first to estimate the MCIDs in treatment outcomes for SJS and TEN. This study defines consensus parameters that are necessary to calculate samples size for prospective studies and evaluate treatment outcomes for SJS and TEN. These findings are necessary to design randomized trials and interpret their results in a clinically meaningful way that can ultimately influence clinical practice. 12-Hydroxyeicosatetraenoic acid levels are increased in actinic keratoses and squamous cell carcinoma
To the Editor: Actinic keratoses (AKs) and squamous cell carcinomas (SCCs) are common skin lesions that are often caused by ultraviolet (UV)einduced photocarcinogenesis. It is well known that UV induces increased expression of cyclooxygenase 2 (COX-2) and production of prostaglandin E 2 in human skin. Although the arachidonic acid metabolism pathway has been studied extensively, the role of its downstream products in carcinogenesis has not been evaluated in human skin. The lipoxygenase (LOX) pathway is known to play a critical role in skin tumor progression in mouse models 1 ; however, its relevance to nonmelanoma skin cancer is less well established. 12-Hydroxyeicosatetraenoic acid (12-HETE) is a potent proinflammatory chemotactic mediator found in higher concentrations in sunexposed skin that is known to drive carcinogenesis in a manner similar to prostaglandin E 2 .
1,2 The UDPglucuronosyltransferases (UGTs) have been shown to be downregulated in primary melanocyte and keratinocyte cell lines after UV exposure. 3 It is hypothesized that UGT activity is reduced during skin cancer progression, resulting in increased 12-HETE signaling. Our objective was to measure levels of 12-HETE in human AK and SCC biopsies.
12-HETE expression was measured quantitatively by using mass spectrometry in nonlesional skin, AKs, and SCCs. A 3-fold increase was noted in AKs and a 20-fold increase in SCCs (Fig 1) compared with nonlesional skin. Both of these increases were statistically significant (P \ .01). Immunohistochemistry was used to detect enzyme expression of UGT in nonlesional skin and SCC skin. When paraffinembedded tissue of nonlesional skin and SCC skin were stained for UGT (Fig 2) , both UGT1A and UGT2B were expressed throughout the epidermis. The expression of these 2 proteins in nonlesional skin appeared to be exclusively cytoplasmic because no staining was detected in the nuclei. The opposite staining pattern was observed in SCC tissue. Both UGT1A and UGT2B expression appeared to be almost exclusively nuclear. This striking difference in expression patterns suggests that UGTs are dysregulated in SCCs. The staining of AKs for UGT was highly variable and showed no consistent pattern.
Several UGT1A polymorphic variants have been found to be associated with an increased risk for SCC of the head and neck. 4 Thus, it is possible the mislocalized UGTs observed in this study are polymorphic variants. Our findings support the hypothesis that nonmelanoma skin cancer progression involves deregulation of the LOX pathway, specifically 12-HETE. Most importantly, this data provides evidence that an effective chemopreventive agent might need to target both pathways of arachidonic acid metabolism, particularly prostaglandin E 2 and 12-HETE. The finding of elevated 12-HETE levels coupled with altered UGT localization in AK and SCC skin suggests that deregulated LOX signaling plays a role in tumor progression and that the LOX signaling pathway could serve as a potential therapeutic target. In a clinical trial, the chemopreventive role of the COX-2 inhibitor celecoxib was evaluated; the results of this study suggested that COX-2 inhibition could slow nonmelanoma skin cancer progression. 5 We hypothesize that celecoxib does not prevent new precancerous lesions because it does not inhibit 12-LOX (an enzyme in the LOX Fig 1. 12-HETE levels in nonlesional skin, AKs, and SCC. 12-HETE levels were measured in nonlesional skin, AKs, and SCCs, and 12-HETE was found to be elevated in AK and SCC skin. 12-HETE, 12-Hydroxyeicosatetraenoic acid; AK, actinic keratosis; SCC, squamous cell carcinoma.
